Solco Biomedical Balance Sheet Health
Financial Health criteria checks 3/6
Solco Biomedical has a total shareholder equity of ₩19.0B and total debt of ₩23.4B, which brings its debt-to-equity ratio to 123.4%. Its total assets and total liabilities are ₩50.7B and ₩31.7B respectively.
Key information
123.4%
Debt to equity ratio
₩23.43b
Debt
Interest coverage ratio | n/a |
Cash | ₩4.52b |
Equity | ₩18.98b |
Total liabilities | ₩31.70b |
Total assets | ₩50.68b |
Recent financial health updates
No updates
Financial Position Analysis
Short Term Liabilities: A043100's short term assets (₩24.3B) do not cover its short term liabilities (₩26.0B).
Long Term Liabilities: A043100's short term assets (₩24.3B) exceed its long term liabilities (₩5.7B).
Debt to Equity History and Analysis
Debt Level: A043100's net debt to equity ratio (99.6%) is considered high.
Reducing Debt: A043100's debt to equity ratio has increased from 32% to 123.4% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: A043100 has sufficient cash runway for 5 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: A043100 is forecast to have sufficient cash runway for 5 months based on free cash flow estimates, but has since raised additional capital.